These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 22004943)

  • 1. Life prolonging of disease management programs in patients with type 2 diabetes is cost-effective.
    Drabik A; Büscher G; Sawicki PT; Thomas K; Graf C; Müller D; Stock S
    Diabetes Res Clin Pract; 2012 Feb; 95(2):194-200. PubMed ID: 22004943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of a quality improvement collaborative focusing on patients with diabetes.
    Schouten LM; Niessen LW; van de Pas JW; Grol RP; Hulscher ME
    Med Care; 2010 Oct; 48(10):884-91. PubMed ID: 20808258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a chronic disease management service for patients with diabetes on hospitalisation and acute care costs.
    Rasekaba TM; Lim WK; Hutchinson AF
    Aust Health Rev; 2012 May; 36(2):205-12. PubMed ID: 22624643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a survival benefit within a German primary care-based disease management program?
    Miksch A; Laux G; Ose D; Joos S; Campbell S; Riens B; Szecsenyi J
    Am J Manag Care; 2010 Jan; 16(1):49-54. PubMed ID: 20148605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of activated protein C in real-life clinical practice.
    Dhainaut JF; Payet S; Vallet B; França LR; Annane D; Bollaert PE; Le Tulzo Y; Runge I; Malledant Y; Guidet B; Le Lay K; Launois R;
    Crit Care; 2007; 11(5):R99. PubMed ID: 17822547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study.
    Almbrand B; Johannesson M; Sjöstrand B; Malmberg K; Rydén L
    Eur Heart J; 2000 May; 21(9):733-9. PubMed ID: 10739728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of preventive screening programmes for type 2 diabetes mellitus in Germany.
    Schaufler TM; Wolff M
    Appl Health Econ Health Policy; 2010; 8(3):191-202. PubMed ID: 20408603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
    Tunis SL
    Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with type 2 diabetes benefit from primary care-based disease management: a propensity score matched survival time analysis.
    Drabik A; Büscher G; Thomas K; Graf C; Müller D; Stock S
    Popul Health Manag; 2012 Aug; 15(4):241-7. PubMed ID: 22401149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US.
    Tunis SL; Minshall ME
    Curr Med Res Opin; 2010 Jan; 26(1):151-62. PubMed ID: 19919376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
    Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year outcome of a prospective, controlled study of a disease management programme for elderly patients with heart failure.
    Del Sindaco D; Pulignano G; Minardi G; Apostoli A; Guerrieri L; Rotoloni M; Petri G; Fabrizi L; Caroselli A; Venusti R; Chiantera A; Giulivi A; Giovannini E; Leggio F
    J Cardiovasc Med (Hagerstown); 2007 May; 8(5):324-9. PubMed ID: 17443097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [General practitioners' opinion and attitude towards DMPs and the change in practice routines to implement the DMP "diabetes mellitus type 2"].
    Miksch A; Trieschmann J; Ose D; Rölz A; Heiderhoff M; Szecsenyi J
    Z Evid Fortbild Qual Gesundhwes; 2011; 105(6):427-33. PubMed ID: 21843845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
    Tunis SL; Willis WD; Foos V
    Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Gender-specific differences in quality of life of patients with type 2 diabetes with or without participating in DMP].
    Miksch A; Hermann K; Trieschmann J; Roelz A; Heiderhoff M; Laux G; Rosemann T; Szecsenyi J
    Gesundheitswesen; 2008 Apr; 70(4):250-5. PubMed ID: 18512199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results of a survey of insurance customers participating in a DMP for diabetes mellitus type 2 of BARMER Health Insurance, Neubrandenburg].
    Elkeles T; Heinze S; Eifel R
    Gesundheitswesen; 2007 Jan; 69(1):18-25. PubMed ID: 17347928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost of diabetes: comparison of disease-attributable and matched cohort cost estimation methods.
    Tunceli O; Wade R; Gu T; Bouchard JR; Aagren M; Luo W
    Curr Med Res Opin; 2010 Aug; 26(8):1827-34. PubMed ID: 20491613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Juvenile obesity and comorbidity type 2 diabetes mellitus (T2 DM) in Germany: development and cost-of-illness analysis].
    Wolfenstetter SB
    Gesundheitswesen; 2006 Oct; 68(10):600-12. PubMed ID: 17099820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
    St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
    Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluating the effectiveness of a disease management program diabetes in the German Statutory Health Insurance: first results and methodological considerations].
    Drabik A; Graf C; Büscher G; Stock S
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(9):649-55. PubMed ID: 23200208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.